×
SABCS 2020 Overview
https://www.sabcs.org/2020-SABCS/2020-SABCS-Overview

Meeting Goals/Purpose, Target Audience, Meeting Location, Contact Information, Preliminary Schedule, Executive Committee, Program Planning Committee, Accreditation, Important 2020 Cutoff Dates

SABCS 2020 Frequently Asked Questions (FAQs)
https://www.sabcs.org/2020-SABCS/FAQs

Symposium Information, Program Schedule, Registration, Abstract Submission, Housing Instructions, Food & Beverage, Media Section, Abstracts On-line, About SABCS, Scholarships, Travel & Transportation

SABCS 2020 Symposium Overview
https://www.sabcs.org/Symposium-Overview-2020

Meeting Profile, Symposium Objective, Scientific Program, Target Audience, Financial Philosophy

SABCS 2020 Call for Abstracts
https://www.sabcs.org/2020-SABCS/Call-for-Abstracts

Preparation, Submission Fee, Submission, Abstract Subject Categories

2019 SABCS Overview
https://www.sabcs.org/2019-SABCS-sup-sup-/2019-SABCS-Overview

Oct 27th, 2019 - This Symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers.

San Antonio Breast Cancer Symposium®: 2019 SABCS®
https://www.sabcs.org/2019-SABCS

Oct 27th, 2019 - An international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer The San Antonio Breast Cancer Symposium is presented by the Cancer Therapy & Research Center at UT Health Science Center San Antonio, the American Association for Cancer Research, and Baylor College of Medicine. The driving force behind this collaboration is the shared m...

SABCS Schedule at a Glance
https://www.sabcs.org/Program/Schedule-at-a-Glance

Oct 27th, 2019 - The San Antonio Breast Cancer Symposium An international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer. The San Antonio Breast Cancer Symposium® is presented by the Cancer Therapy & Research Center at UT Health Science Center San Antonio, the American Association for Cancer Research, and Baylor College of Medicine.

SABCS 2019 FAQs
https://www.sabcs.org/2019-SABCS-sup-sup-/2019-FAQs

Oct 27th, 2019 - This Symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant disease, to an international audience of academic and private physicians and researchers. The Symposium provides a forum for interaction, communication, and education for a broad spectrum of researchers, health professiona...

SABCS 2019 Symposium Overview
https://www.sabcs.org/Symposium-Overview-2019

Oct 27th, 2019 - Since 1977, the Symposium’s mission has been to provide state-of-the-art information on breast cancer research. From a one-day regional conference, the Symposium has grown to a five-day program attended by a broad international audience of academic and private researchers and physicians from over 90 countries.

Susan G. Komen Names Three Recipients of the 2019 Brinker Awards for Scientific Distinction
https://ascopost.com/issues/october-25-2019/komen-names-recipients-of-brinker-awards-for-scientific-distinction/

Oct 24th, 2019 - Jane Visvader, PhD Geoffrey Lindeman, MBBS, PhD Matthew J. Ellis, BSc, MB, BChir, PhD, FRCP Susan G. Komen recently named Jane Visvader, PhD; George Lindeman, MBBS, PhD; and Matthew J. Ellis, BSc, MB, BChir, PhD, FRCP, as this year’s recipients of the Brinker Awards for Scientific Distinction. The 2019 Brinker Award winners will deliver keynote lectures at the upcoming 2019 San Antonio Breast C...

Brinker Award winners to speak at #SABCS19
https://www.sabcs.org/2019-SABCS-sup-sup-/Blogs/ArticleID/176/Brinker-Award-winners-to-speak-at-SABCS19

Oct 13th, 2019 - Susan G. Komen® recently announced the recipients of the 2019 Brinker Awards for Scientific Distinction. They will receive their awards and present lectures at the 2019 San Antonio Breast Cancer Symposium® (SABCS®) at the Henry B. Gonzalez Convention Center, Dec. 10-14.

Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibit...
https://doi.org/10.1007/s10549-019-05464-w
Breast Cancer Research and Treatment; Qian X, Li Z et. al.

Oct 13th, 2019 - Endocrine therapy with aromatase inhibitors (AIs) is the cornerstone of adjuvant systemic treatment for postmenopausal patients with hormone receptor-positive breast cancer. It has become clear that hormone receptor-positive breast cancer carries a consistent risk of relapse up to 15 years after diagnosis. Extended duration of adjuvant AIs therapy after completing initial standard adjuvant AIs-...

Puré and Weichselbaum to present plenary lectures
https://www.sabcs.org/2019-SABCS-sup-sup-/Blogs/ArticleID/175/Pur%C3%A9-and-Weichselbaum-to-present-plenary-lectures

Oct 6th, 2019 - Ellen Puré, PhD and Ralph Weichselbaum, MD, will present the plenary lectures at the 2019 San Antonio Breast Cancer Symposium® (SABCS®), Dec. 10-14.

SABCS selects abstracts, releases schedule
https://www.sabcs.org/2019-SABCS-sup-sup-/Blogs/ArticleID/174/SABCS-selects-abstracts-releases-schedule

Sep 18th, 2019 - Abstracts have been selected and presenters notified of their acceptance for the 2019 San Antonio Breast Cancer Symposium® Dec. 10-14 at the Henry B. Gonzalez Convention Center. More than 1,700 oral, spotlight and poster presentations will await attendees to the 42nd annual symposium which is the premier scientific conference focused solely on premalignant breast disease and breast cancer.

Joseph A. Sparano, MD, to Receive William L. McGuire Memorial Lecture Award
https://ascopost.com/issues/august-10-2019/joseph-a-sparano-md-to-receive-william-l-mcguire-memorial-lecture-award/

Aug 9th, 2019 - Joseph A. Sparano, MD, will receive the William L. McGuire Memorial Lecture Award at the 2019 San Antonio Breast Cancer Symposium (SABCS), to be held December 10–14. The McGuire Award was established in 1992 to honor William L. McGuire, MD, who, along with Charles A. Coltman, MD, founded the SABCS in 1977. Joseph A. Sparano, MD Dr. Sparano is being recognized for a career distinguished by leade...

Forums offer insights for early-career investigators
https://www.sabcs.org/2019-SABCS-sup-sup-/Blogs/ArticleID/171/Forums-offer-insights-for-early-career-investigators

Jul 28th, 2019 - The San Antonio Breast Cancer Symposium® is not only the leading scientific conference on the diagnosis and treatment of premalignant breast disease and breast cancer, there are outstanding opportunities for young scientists, clinicians and investigators to gain vital career insights.

SABCS awards Joseph A. Sparano the William L. McGuire Memorial Lecture Award
https://www.sabcs.org/2019-SABCS-sup-sup-/Blogs/pageindex10112/2

Jul 7th, 2019 - Joseph A. Sparano, MD will receive the William L. McGuire Memorial Lecture Award at the 2019 San Antonio Breast Cancer Symposium.

Evidence Lacking That Denosumab Alters the Course of Breast Cancer
https://ascopost.com/issues/june-25-2019/evidence-lacking-that-denosumab-alters-the-course-of-breast-cancer/

Jun 24th, 2019 - I am writing to provide personal context to my column on adjuvant denosumab or bisphosphonates for resected breast cancer, which appears on page 52 in this issue of The ASCO Post. I have been upset since 2013 that adjuvant zoledronate has been recommended for women with breast cancer onset after age 55 without a positive trial restricted to this population showing benefits in the incidence of b...

Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negativ...
https://meetinglibrary.asco.org/record/171873
Adam Brufsky, MD, PhD

Jun 2nd, 2019 - Background: COLET showed that the addition of C (MEK1/2 inhibitor) to P resulted in an increased ORR (38%; Brufsky, SABCS 2017); IMpassion130 demonstrated clinical benefit with the combination of PD-L1 inhibitor A and nP as 1L tx for pts with mTNBC (Schmid, N Engl J Med, 2018). We investigated the efficacy and safety of A + C + P/nP in pts with mTNBC, as this combination may target multiple can...